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Abstract: Patient-centered motives and expectations of the treatment of actinic keratoses (AK) have
received little attention until now. Hence, we aimed to profile and cluster treatment motivations and
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expectations among patients with AK in a nationwide multicenter, cross-sectional study including
patients from 14 German skin cancer centers. Patients were asked to complete a self-administered
questionnaire. Treatment motives and expectations towards AK management were measured on
a visual analogue scale from 1–10. Specific patient profiles were investigated with subgroup and
correlation analysis. Overall, 403 patients were included. The highest motivation values were
obtained for the items “avoid transition to invasive squamous cell carcinoma” (mean ± standard
deviation; 8.98 ± 1.46), “AK are considered precancerous lesions” (8.72 ± 1.34) and “treating physician
recommends treatment” (8.10 ± 2.37; p < 0.0001). The highest expectation values were observed
for the items “effective lesion clearance” (8.36 ± 1.99), “safety” (8.20 ± 2.03) and “treatment-related
costs are covered by health insurance” (8.00 ± 2.41; p < 0.0001). Patients aged ≥77 years and those
with ≥7 lesions were identified at high risk of not undergoing any treatment due to intrinsic and
extrinsic motivation deficits. Heat mapping of correlation analysis revealed four clusters with
distinct motivation and expectation profiles. This study provides a patient-based heuristic tool for a
personalized treatment decision in patients with AK.
Keywords: skin cancer; patient education; actinic keratosis; cross-sectional study; patient-centered
care; patient-reported outcomes; personalized medicine
1. Introduction
Long-term exposure to ultraviolet (UV) radiation can lead to the formation of actinic keratoses (AK)
in light-skinned individuals [1,2]. Lesions present as diffuse red and keratotic or scaling plaques with a
rough, sandpaper-like surface on chronically sun-exposed areas such as the face, ears, arms, and dorsal
hands [2,3]. AK lesions are considered precursors of invasive cutaneous squamous cell carcinoma
(cSCC), although the conversion risk for an individual lesion to progress into cSCC is estimated low [4].
The presence of multiple lesions, marked basal proliferation in histology, and additional signs of chronic
UV damage on the adjacent skin increases the risk for progression considerably, and spontaneous
regression is less likely to occur [5–7]. As it is clinically not possible to exactly predict which AK
will become invasive cSCC, international treatment guidelines recommend early and consequent
treatment [8,9]. Today, numerous interventions with varying efficacy and safety profiles are licensed
for the management of AK. These comprise lesion-directed therapies such as excision or cryosurgery
as well as field-directed therapies including photodynamic therapy (PDT) or topical interventions,
which target a whole area of skin bearing multiple AK and aim at clearing subclinical changes [10].
However, the individual effect of the respective treatment strongly depends on patients’ willingness
and consent to adhere to the treatment regimen. Almost all AK treatments carry a therapeutic burden
such as pain, adverse events, costs, treatment duration, altered cosmetic appearance, local skin reactions
or inconvenience of application. These factors may influence the underlying motives of patients to
be willing to undergo or choose a specific intervention [11]. Understanding treatment motivation,
expectations, and individual patient preferences critically influence the treatment success. Besides,
these factors are important to improve the acceptability of and compliance to treatment regimens [11,12].
Surprisingly, the patient-centered motives and expectations towards AK treatment have received little
attention until now but can represent a major barrier for treatment adherence [13–15]. Here, we report
the results of a German-wide, multicenter, cross-sectional study to gain insight into the management of
AK by investigating patient attitudes, expectations, and motives.
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2. Materials and Methods
2.1. Study Design and Ethics Approval
A multicenter, cross-sectional study that included patients from 14 German skin cancer centers was
conducted between May and August 2019. This study was approved by the institutional review board
of the University Hospital (LMU Munich) on 7 June 2019 (approval number 19-356 KB, Supplementary
A1). We closely adhered to the STROBE statement for cross-sectional studies for the reporting of this
study (Supplementary A2) [16,17].
2.2. Setting and Participants
Adult patients (≥18 years) presenting with AK in the participating centers were asked either by a
physician or a nurse to complete a self-administered four-page questionnaire (purposive sampling,
Supplementary A3). As the first page of the questionnaire included questions related to previous
treatments, number, and localization of AK, patients were allowed to ask the physician for advice and
to obtain patient-specific information, if necessary. Participation was voluntary and all participants
gave verbal informed consent before completing the questionnaire. Refusals were not documented,
and no incentives were provided. Relatives or accompanying persons were excluded from the study.
Each patient was allowed to participate only once in the survey (cross-sectional design).
2.3. Survey
As no validated survey tools for the objective of our study existed, the questionnaire was developed
de novo based on a literature review and thorough dermatologic expert consulting. The questionnaire
included items on previous treatments for AK, localization and number of lesions, immunosuppression,
underlying motives to undergo AK treatment and expectations and wishes towards therapy as well
as basic demographic information (age, gender, marital status, health insurance status, profession).
Patients with an increased UV exposure due to their long-term profession were categorized as at
high risk for developing skin cancer. For the questions related to motives and expectations towards
AK treatment, patients were asked to rate the level of agreement on a continuous visual analogue
scale (VAS) ranging from 0 (do not agree) to 10 (fully agree). The full questionnaire is available in
Supplementary A3. The questionnaire was pre-tested and validated for clarity and comprehension
by independent researchers who were not involved in the design of the original questionnaire and
volunteering patients without AK. Unclear items were thoroughly discussed and rephrased until a
consensus on clarity was reached. Based on this feedback, questions were simplified, the questionnaire
was shortened and finally, the questionnaire was revised to its final version. Completed questionnaires
were sequentially numbered for data entry purposes but were not linked to any identifying patient
information to assure irreversible anonymity.
2.4. Data Analysis
We calculated an estimated sample size of at least n = 320 required for this explorative study
design as suggested by Tabachnik and Fidell by multiplying the number of the questionnaires’ items
by factor 10 [18]. Statistical analyses were conducted with SPSS (IBM SPSS Statistics version 24, IBM
Corporation, Armonk, NY, USA). Descriptive analyses included means with standard deviations (SD)
or medians and interquartile ranges (IQR). Categorical variables were expressed as frequencies and
percentages. Subgroup differences between two groups were explored with the student’s t-test or
Mann-Whitney-U-test. For the comparison of more than two groups, one-factor analysis of variance
followed by Scheffé procedure or the Kruskal-Wallis test was used. The relationship between the level
of agreement of patient motives and expectations towards AK therapy were examined with Spearman’s
correlation. A two-sided p-value < 0.05 was considered statistically significant in all cases. Missing
values were excluded pairwise. Besides, missing data were addressed by indicating the number of
participants considered in each analysis.
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3. Results
3.1. Characteristics of the Study Population
A total of 403 patients were included. The majority was male (73.7%; 294/399) and the median
age at the time of the visit was 77 years with a range from 43 to 94 years. 73.5% (291/396) of the
patients were married, 15.7% (62/396) were widowed followed by 5.6% who were divorced (22/396)
or single/unmarried (5.3%; 21/396). Besides, most patients had statutory health insurance (76.8%,
304/396). 7.9% (30/382) of patients stated to take immunosuppressive medication, the majority
(n = 17) due to organ transplantation. Of these, 11 patients were renal transplant recipients, one
had a transplanted liver and five transplant recipients did not provide information regarding their
transplanted organ. The remaining patients stated to have an autoimmune disease (16.7%, n = 5) or to
take immunosuppressive medications due to other reasons, such as rheumatoid arthritis (n = 1) or
ankylosing spondylitis (n = 1), representing a risk population for the development of AK (Table 1).
The majority of patients (91.0%; 303/333) were classified as not having an increased risk for skin cancer.
Patients presented predominantly with AK located in the face or scalp (65.6%; 261/398). In contrast,
23.9% (95/398) had AK both on the scalp and facial sites as well as in non-head and non-facial regions.
The remaining 10.6% (42/398) showed AK only on the extremities or trunk. Nearly half of the patients
had 1–3 AK treated at the time of the visit (47.6%, 167/351), followed by ≥7 AK (29.9%, 105/351) and
4–6 AK (22.5%, 79/351). Overall, 83.6% (331/396) of the patients reported at least one pre-treatment,
whereas 15.4% (61/396) did not have any prior treatment and 1% (4/396) could not remember. Nearly
half of the patients (46.4%; 153/330) voted to have had their AK treated at least once with diclofenac
sodium 3% in hyaluronic acid 2.5% gel, followed by PDT (38.8%; 128/330) and surgical excision (37.3%;
123/330) (Supplementary Figure S1).
Table 1. Baseline characteristics of the study population.
Sample % (n)
Sex (n = 399)
Female 26.3 (105)
Male 73.7 (294)
Age (n = 395)
years (median, range) 77 (43–94)
years (mean ± standard deviation) 75.10 ± 9.45
Family status (n = 396)
Single/unmarried 5.3 (21)
Married 73.5 (291)
Divorced 5.6 (22)
Widowed 15.7 (62)
Risk exposure for skin cancer (n = 333)
Yes 9.0 (30)
No 91.0 (303)
Health insurance (n = 396)
Statutory health insurance 76.8 (304)
Private health insurance 23.2 (92)
Immunosuppression (n = 382)
No 92.1 (352)
Yes 7.9 (30)
Organ transplant recipient 56.7 (17)
Autoimmune disease 16.7 (5)
Other 26.7 (8)
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Table 1. Cont.
Sample % (n)
Previous treatment of AK (n = 396)
Yes 83.6 (331)
No 15.4 (61)
Unsure 1.0 (4)
Last treatment of AK (n = 292)
months (median, range) 6 (0–300)
months (mean ± standard deviation) 18.62 ± 32.35
Number of AK to be treated at the visit (n = 351)
1–3 47.6 (167)
4–6 22.5 (79)
≥7 29.9 (105)
Outdoor profession (n = 333)
Yes 9.0 (30)
No 91.0 (303)
Localization of AK (n = 398)
Scalp 57.3 (228)
Face 61.6 (245)
Trunk 8.0 (32)
Extremities 31.4 (125)
Only face/scalp 65.5 (261)
Only trunk/extremities 10.6 (42)
All sites 23.9 (95)
3.2. Items of Treatment Motivation
Patients strongly agreed to undergo treatment to avoid the transition of AK to invasive
cSCC (mean ± standard deviation: 8.98 ± 1.46) or since AK are considered precancerous lesions
(8.72 ± 1.34) (Figure 1A). Interestingly, patients also agreed to undergo treatment due to the physician’s
recommendation (8.10 ± 2.37) or because medical guidelines recommend treatment (7.19 ± 2.67).
In contrast, patients rather disagreed that cosmetic reasons (2.49 ± 2.84) and treatment due to the
desire of third parties such as relatives (3.35 ± 3.45) were motivating factors (p < 0.0001). Other reasons
specifically mentioned by the patients in a free-text field included aesthetic restrictions in general (n = 3),
improvement of the professional appearance (n = 1), pain relief (n = 3), or improvement of quality
of life (n = 1). Next, we investigated whether the treatment motivations varied according to clinical
and socio-demographic parameters and performed subgroup analyses. Significant differences among
the subgroups are shown in Figure 2A. Further information can be obtained from the supplementary
results (Appendix A.1).
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3.3. Items of Treatment Expectation
Patients strongly expected effective AK lesion clearance (8.36 ± 1.99) (Figure 1B). Safety of the
individual interventions was also considered important (8.20 ± 2.03), followed by the coverage of
treatment-related costs by health insurance funds (8.00 ± 2.41). Furthermore, patients expected that the
treatment has a proven long-term efficacy (7.80 ± 2.32) and few or no side effects (7.77 ± 2.33). Further
patient preferences included simplicity of the individual intervention (7.70 ± 2.39), no interference
with everyday life (7.43 ± 2.55) and that the treatment is hardly to minimally painful (7.25 ± 2.58).
Additionally, patients estimated a good cosmetic outcome (6.60 ± 2.77), short treatment course
(6.31 ± 2.97) and little costs (6.24 ± 2.83) as important. Lower values were obtained for home-based
treatment (5.77± 3.56) and a one-time treatment procedure (5.40± 3.35; p < 0.0001). Further reasons that
were specifically addressed by patients in the free-text field included the wish for regular surveillance
and better education regarding the dangers and avoidance of sunlight by physicians (n = 2), long-term
clearance (n = 6) or no occurrence or spread of skin cancer (n = 6).
Next, we performed subgroup analysis for the motivation items. Significant differences among the
subgroups are shown in Figure 2B. In particular, patients aged >77 years and those with >7 lesions were
unsure why treatment was indicated. Further information can be obtained from the supplementary
results (Appendix A.2).
3.4. Correlation Analysis of Motivation and Expectation Items
To identify distinct patient profiles and clusters of patient subgroups, we performed Spearman’s
correlation of the individual motivation and expectation items. As most items were correlated with
each other, we focused on correlations that were most strongly correlated (i.e., r > 0.5 or r < −0.2).
The recommendation of the physician for treatment was positively correlated with the motivation to
have AK treated as they are considered precancerous lesions (r = 0.547) (Figure 3). Furthermore, the
item “avoid progression to invasive cSCC” was also correlated with the motivation to treat AK because
they are perceived precancerous lesions (r = 0.670). There was also a trend that patients who agreed to
desire a short treatment wished for treatment to be performed only once (r = 0.557). Patients voting a
proven long-term effect as important tended to rate effective lesion clearance to be important (r = 0.682)
as well as safe treatment (r = 0.639). Effective lesion clearance was additionally positively correlated
with safe treatment (r = 0.535). Another correlation was identified for treatments with hardly or no
adverse events and simplicity of treatment (r = 0.606). There was also a correlation between the desire
for an intervention that does not interfere with daily life and one that is perceived to be hardly or not
painful (r = 0.557). Additionally, the item “unclear why AK needs to be treated” and age were slightly
significantly correlated with each other. All correlations were statistically highly significant (p < 0.01).
3.5. Clustering Treatment Motivation and Expectation Items to Define Distinct Patient Populations
Based on the heat map of these data, we identified two distinct clusters for treatment motivation
(clusters 1 + 2) and treatment expectation (clusters 3 + 4), respectively (Figure 3). Cluster 1 comprised
the items “physician’s recommendation”, “AK as precancerous condition”, and “avoid transition to
invasive cSCC (Table 2). Cluster 2 was dominated by the negatively correlated items “unclear why
AK need to be treated”, “physician’s recommendation”, “AK as precancerous condition”, and “avoid
transition to invasive cSCC”. Within this cluster “unclear why AK need to be treated” and “desire of
relatives” was positively correlated with each other. Cluster 3 comprised “simplicity”, “safety”, “few
adverse events”, “little painfulness” and “no impairment in daily life”, and cluster 4 “safety”, “few
adverse events”, “little painfulness”, “effective lesion clearance”, and “long-term efficacy”. All items
of clusters 1, 3, and 4 were positively correlated.
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Table 2. Summary of treatment motivation and treatment expectation profiles.
Treatment Motivation Treatment Expectation
Cluster 1 Cluster 2 Cluster 3 Cluster 4
Leading
item
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4. Discussion
This cross-sectional study was designed to investigate individual, patient-centered motives and
expectations towards the treatment of AK which have not received much attention until now but
should ultimately be considered when a treatment choice is made. Furthermore, we aimed to identify
distinct patient profiles that could provide a valuable and heuristic resourc to facilitate personalized
decision-making in the daily routine. For the first time, we define distinct patient profiles for the
treatment of AK based on primary patient-derived data. A previous study defined six profiles based
on the experience of an expert panel. However, patients themselves or patient representatives were not
involved whe the profiles were derived [19]. In analogy to other dermatologic conditions, we believe
that it is indispensable to use patient-derived data as a primary source to outline specific profiles
and to guide patient-cent red reatment [20,21]. Thus, we collected data on the trea ment mo ivation
and expectation from a larg cohort of 403 patie s distribute among 14 major centers for AK care
within Germa y. Ov rall, the highest motivation for AK trea ment was to avoid the transition to
invasive cSCC, because AK are considered precancerous lesions, an because the treating physician
recommends treatment. These motivation items also achieved uniformly high values on the VAS in the
subgroup analysis. The highest expectation values were obtained for effective lesion clearance, the
safety of the intervention, and that th treatment costs are covered by health insurance. We conclude
that these factors should be considered and highlighte for ny t eatment decision.
Nowadays, choosing an appropriate and individualized intervention often largely depends on
the knowledge, expertise, and preference of the practitioner as well as reimbursement status and
may be insufficiently aligned with the individual desire of the patient [22,23]. In a recent qualitative
study among physicians, cryosurgery was cited as the predominant therapy because other forms of
therapy were little known or because there was uncertainty about their use [24]. Nevertheless, most
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dermatologists in this qualitative survey stated that they were aiming for guideline-based therapy,
which was also an important motivation for patients in our study. Among all items of motivation
in our survey, it achieved the third-highest average values, albeit with a high degree of variability.
Interestingly, this motivation was higher for patients with statutory health insurance than for those
with private health insurance. This could be possibly explained by the fact that patients with statutory
health insurance suspect that therapy in line with the guidelines is also fully reimbursed and that this
does not result in any financial losses for them. A concrete counterexample is conventional PDT, which
is uniformly recommended in current treatment guidelines [8,9] but has not yet been reimbursed by
the statutory health insurance funds in Germany.
To further dissect and identify specific profiles, we performed subgroup analyses and correlated
the motivation and expectation items with each other and with the baseline characteristics. Cosmesis
showed rather low motivation values in the overall population. However, it was rated significantly
higher in patients with low occupational UV exposure and a non-immunocompromised status.
Furthermore, the expectation of a good cosmetic outcome was higher in women and patients with
AK located on the face or head. Interestingly, patients whose AK had never been treated before and
those with few AK (1–3 lesions) rather expected a one-time treatment, indicating that they may not yet
be aware that AK is a chronic condition, which usually requires multiple treatment modalities and
lifelong surveillance [5]. We propose that it is critical to provide substantial information framing on the
disease course and to ensure sufficient communication and patient education for this subgroup [25].
Treating physicians must actively approach and educate this subgroup, especially those who undergo
AK treatment for the first time.
The correlation analysis between motives and expectations revealed that patients who underwent
treatment to prevent progression to invasive cSCC mainly desired an effective, long-lasting, safe, and
simple approach that does not interfere with daily life and whose costs are covered by health insurance.
Similarly, patients undergoing AK treatment due to the physician’s recommendation preferred an
effective and safe therapy that is reimbursed by health insurance. In contrast, those who underwent
treatment for cosmetic reasons expected a good cosmetic result while being less interested in the
efficacy and safety of the procedure. The heat-map of the correlation analyses revealed four clusters
with highly positively (clusters 1, 3, 4) and negatively (cluster 2) correlated items. For motivation, we
identified two distinct clusters. While cluster 1 appeared easily and highly motivated for treatment
both intrinsically and extrinsically by the physician’s recommendation, cluster 2 may have a high risk
of not undergoing any therapy due to motivation deficits. Older patients (>77 years) and those with
≥7 lesions were particularly unsure why their conditions needed to be treated, although they carry a
high risk of developing an invasive cSCC. As they were less motivated by treating physicians, relatives
and third parties may be approached to assure adherence to treatment in this subgroup. Although the
relatives’ desire for treatment was rated rather less important as motivation in the overall population,
the values for this item were significantly higher for the subgroups age ≥77 years, men, and localization
of lesions on the head or face.
Among treatment expectations, we identified two more clusters whose items were positively
correlated. Patients of cluster 3 expected both efficacy and safety measures as well as no impairment in
daily living along with the intervention. We conclude that patients of cluster 3 are therefore moderately
motivated for treatment if everyday life is not affected by the interventions chosen. In contrast, safety,
efficacy, and tolerability were the main domains for patients of cluster 4. Although these patients appear
highly motivated to undergo treatment, they also have high expectations towards the interventions.
We believe that considering and balancing these preferences will help to ensure adherence to treatment
and facilitate ideal treatment outcomes.
We are aware that this study has several limitations. The sample comprised 403 patients recruited
during a short period. This sample size is relatively small, and the study population was not sampled
randomly but depending on the availability of patients. Most questionnaires have been obtained
from the University Hospital Munich, hence this overrepresentation may skew the results, although
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we believe that geographic or inter-city diversity can be neglected due to the small size of Germany.
Besides, participants with high cumulative sun exposure were underrepresented which may limit the
external validity of this study. Thus, the results presented here may not be fully generalizable to the
general population and are at risk for sampling bias.
5. Conclusions
This study provides a patient-based heuristic tool to facilitate personalized treatment decisions in
patients with AK. Considering patient profiles and individual preferences are of paramount importance
to ensure patient adherence and to achieve ideal treatment outcomes. Nevertheless, the choice of the
intervention should be made on a case-by-case basis and thoroughly discussed to reach an informed
treatment consensus.
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Appendix A
Supplementary results: Subgroup analysis of treatment motivation items and subgroup
analysis of treatment expectation items
Appendix A.1 Subgroup Analysis of Treatment Motivation Items
We revealed specific subgroup differences for gender and the willingness to undergo treatment
due to the desire of relatives of the patient, i.e., men would rather receive treatment because their
partners want them to do so (p = 0.017) (Figure 2A). The same motivation item also concerned patients
aged ≥77 years in contrast to patients below that age (p = 0.004) and patients with AK located in the
face or head region compared to trunk or extremities (p = 0.046). Additionally, older patients (≥77
years) were rather unsure about the necessity of treatment in comparison to younger patients (p =
0.001). Also, patients with ≥7 lesions were rather unsure about the necessity of treatment compared
to those with 1–3 (p = 0.017) or 4–6 lesions (p = 0.016). Indoor workers stated that cosmesis was a
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motivation for treatment compared to outdoor workers (p = 0.039). Cosmetic outcome was also a
pronounced motivation for immunocompetent patients compared to immunocompromised ones (p
= 0.007). Notably, patients with statutory health insurance rather saw guideline recommendations
as treatment motivation compared to those with private insurance (p = 0.000). Lastly, patients who
have already undergone at least one prior treatment also considered the precancerous nature of AK as
motivation (p = 0.005).
Appendix A.2 Subgroup Analysis of Treatment Expectation Items
Women expected a good cosmetic result compared to men (p = 0.040) (Figure 2B). Patients with
AK localized in the face or on the scalp also rather expected a good cosmetic outcome in comparison
to those with AK on the extremities or trunk (p = 0.009). Furthermore, younger patients (<77 years)
preferred to undergo treatment at home, whereas older patients preferred treatment at the hospital
or practice (p = 0.006). Besides, treatment-naïve patients rather expected treatment to be performed
only once (p = 0.001). Patients with AK located on the face or head area also desired treatment to be
performed only once in comparison to those with AK located on every site of their body (p = 0.031).
Additionally, patients with statutory health insurance preferred home-based treatment in contrast to
those with private insurance (p = 0.001). Patients with statutory health insurance also expected low
treatment costs (p = 0.000) and reimbursement by health insurance (p = 0.018) compared to private
insurance. In comparison to single patients, married (p = 0.012) and widowed ones (p = 0.024) rather
expected treatment to be hardly to little painful. Besides, patients with few AK (1–3) rather voted
that treatment be carried out only once in comparison to those with 4–6 lesions (p = 0.025). However,
in comparison to patients with a medium number of lesions (4–6), patients with 1–3 (p = 0.039) and
patients with ≥7 lesions (p = 0.034) expected effective AK lesion clearance.
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